SV

Street Verdict

Analyst Scorecard

A record of what Nomura Analysis said publicly, with the source. Not advice.

“Nomura maintains a 'Buy' rating on Alkem Labs with a target price of ₹5,430. Q4 sales were in line, though EBITDA and PAT missed estimates. The FY26 guidance is mixed, and a higher effective tax rate of 35-37% in FY27E (vs. 20% earlier) will negatively impact reported earnings, though not cash flows.”

Nomura Analysis’s track record (trackable calls only): 89 graded calls · 95% CI 41–62%

Alkem Laboratories LtdBullishCalled 30 May 2025Graded 12 Sep 2025
Verdict:HIT

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹5,430, as stated.

Window: 12 months, the default when no time frame is stated.

The target ₹5,430 was reached on a close. Hit.

The grader’s working: R4 TARGET_CALL: entered ₹5096.5 on 2025-06-02 (next trading session's close); target ₹5430 reached at close ₹5448 on 2025-09-12. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

Tracking Alkem Laboratories Ltd since this call

1-year tracking window
Read the original articleSee Nomura Analysis’s full track record